Posted by Michael Wonder on 13 Jul 2017
CAR-Ts clear one roadblock but face many more
14 July 2017 - Novartis wins over an FDA panel but the road to commercial viability is long.
A medicine that transforms human immune cells into something that hunts cancer, seemingly eradicating it in weeks in some patients, sounds more like wishful thinking than an actual drug.
But a Novartis medicine that does just this was unanimously recommended for approval by an FDA panel of experts on Wednesday. It will likely be available within months for children and young adults with a hard-to-treat blood cancer.
